AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05613777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®
Description: ethinylestradiol (EE) and levonorgestrel (LNG)
Study NCT05613777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study NCT05395195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Erythropoietin injections (500u/kg) x 9 doses
Study NCT05395195 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Supportive neonatal intensive care
Description: Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
Study NCT05395195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive neonatal intensive care
Description: Neonatal intensive care monitoring and support including ventilatory and inotropic support as clinically indicated
Study NCT06237088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online mindfulness program
Description: The intervention includes an eight-week internet-based mindfulness program. The program introduces participants to a new mindfulness topic every week. These topics are heavily inspired by the eight-week mindfulness programs.
Study NCT05817799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine 500Mg thrice daily
Description: L-Carnitine 500mg oral thrice daily
Study NCT05817799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1g L-Carnitine IV three times a week
Description: 1g IV L-Carnitine three times a week
Study NCT06237088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: eight-week mindfulness programs
Description: The intervention consists of 2.5-hour classes per week over a period of eight weeks.
Study NCT05547698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-pump lung transplantation
Description: General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, pneumonectomy starting by the less perfused lung in the scan, stump preparation, lung implantation, reperfusion, gradual release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, chest closure.
Study NCT05547698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venoarterial ECMO lung transplantation
Description: General anesthesia, intubation with double lumen tube, thoracotomies or clamshell incision, heparin, peripheral or central venoarterial ECMO cannulation, first pneumonectomy, stump preparation, lung implantation, reperfusion, release of the pulmonary artery clamp, deairing, ventilation of the 1st implanted lung. The process is repeated at the contralateral side. Ventilation of both lungs, ECMO decannulation, chest closure.
Study NCT05700968 — intervention group
Intervention type: OTHER
Intervention: validity and reability study
Description: Validity and reliability assessment of the Turkish version of the Multidimensional Outcome Expectations For Exercise Scale (MOEES).
Study NCT04954326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyophilized S95014
Description: Lyophilized S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol.
Study NCT04954326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liquid S95014
Description: Liquid S95014 will be intravenously administered over 1 hour at the dose of 2500 U/m2 at Day 3 of the induction phase.~Patients will receive other backbone chemotherapy agents as per ALL-MB 2015 protocol.
Study NCT06263075 — intervention group
Intervention type: PROCEDURE
Intervention: Intraoperative monitoring
Description: ANESTHESIOLOGICAL MANAGEMENT accords to usual practice. Participants underwent preoperative fasting (3 h for breast milk, 4 h for formula milk, and 1 h for clear liquids), no premedication, induction and maintenance by sevoflurane, fentanyl boluses for analgesia, mechanical ventilation (PEEP 4 cm H2O, target tidal volume 6-8 ml/Kg, end tidal CO2 32-40 mmHg), 10 ml/Kg/h of intraoperative fluids. Scalp block is performed before surgery.~MONITORING DURING SURGERY: monitor devices routinely used are connected to the participant: Dräger Infinity Delta XL®, Masimo® for pulse oximetry (Rainbow SET), regional cerebral oximetry (O3TM), and (optional) brain function monitoring (Masimo® SedLine). Arterial blood gas test is sampled at the anesthesiologist's discretion. After the artery catheterization, the MostCare® system is simultaneously connected to the patient monitoring devices. Data are collected every 3 minutes, 6 minutes for the noninvasive blood pressure measurement.
Study NCT05569213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: motor evoked potentials
Description: see previous descriptions
Study NCT05555147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nerve block with 0.5% ropivacaine
Description: After general anesthesia, the patients will receive bilateral infraorbital and infratrochlear nerve block 30 minutes prior to surgery. Infraorbital nerve block is performed while using an extraoral approach. A 25-gauge needle was inserted laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. The index finger of the non-dominant hand was positioned above the infraorbital foramen, and the needle was advanced until it was felt beneath the finger. 2 ml of the 0.5% ropivacaine slowly injected after negative aspiration of blood was confirmed. Inserting the needle 1 cm above the inner canthus, targeting the junction of the orbit and the nasal bone, performed infratrochlear nerve block. After negative aspiration of blood, 1 ml of the 0.5% ropivacaine was injected. Contralateral nerve block was performed in the same manner.
Study NCT05555147 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: without any nerve block
Description: Patients receiving general anesthesia without Infraorbital and Infratrochlear nerve block.
Study NCT05261841 — intervention group
Intervention type: OTHER
Intervention: Standard care for T2D patients, Smartwatch
Description: No intervention, observational study
Study NCT04917445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spikes-focused bad news protocol
Description: Nurses trained to deliver bad news to IVF patients based on the Spikes-protocol for compassionately delivering bad news to patients.
Study NCT04886115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular evaluation
Description: Before and after training.~Muscle function:~* voluntary maximal isometric force of the knee extensors~* evoked force in the knee extensors by double percutaneous electrical stimulation at 100 and 10 Hz~* level of voluntary activation~* voluntary maximum force in concentric and eccentric mode at an angular speed of 60°.s-1~* squat jump and counter-movement jump
Study NCT04886115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular evaluation
Description: Before and after training.~Muscle function:~* voluntary maximal isometric force of the knee extensors~* evoked force in the knee extensors by double percutaneous electrical stimulation at 100 and 10 Hz~* level of voluntary activation~* voluntary maximum force in concentric and eccentric mode at an angular speed of 60°.s-1~* squat jump and counter-movement jump
Study NCT04886115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of aerobic capacity, muscle architecture and habituation to the eccentric pedaling task
Description: Before and after training.~Cardiovascular-respiratory function:~* Oxygen consumption during the incremental concentric pedaling test conducted to high effort perception.~* heart rate during pedaling tasks~Muscle architecture:~- Pennation angle and thickness of vastus lateralis, rectus femoris, gastrocnemius medialis and lateralis muscles, before and after training.~Familiarization with eccentric pedaling
Study NCT04886115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of aerobic capacity, muscle architecture and habituation to the eccentric pedaling task
Description: Before and after training.~Cardiovascular-respiratory function:~* Oxygen consumption during the incremental concentric pedaling test conducted to high effort perception.~* heart rate during pedaling tasks~Muscle architecture:~- Pennation angle and thickness of vastus lateralis, rectus femoris, gastrocnemius medialis and lateralis muscles, before and after training.~Familiarization with eccentric pedaling
Study NCT04886115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedaling at 15 rpm
Description: 3 training sessions per week for 6 weeks
Study NCT05203679 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Single dose intravenous injection of BBM-H901
Description: Single dose intravenous infusion of BBM-H901, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 1×10\^13 vg/ kg
Study NCT05847907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Implant placement in subject with type 2 diabetes mellitus. Implant placement in subjects with type 2 diabetes mellitus. Implants with BA surface will be placed in one group of subjects and implants with SA surface in the other group.
Study NCT05847907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Implant placement in subject with type 2 diabetes mellitus. Implant placement in subjects with type 2 diabetes mellitus. Implants with BA surface will be placed in one group of subjects and implants with SA surface in the other group.
Study NCT06341140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding support and Booklet containing information about breastfeeding
Description: Pregnant women in the intervention group were given individual counseling with a wearable breastfeeding model. During postnatal home visits, mothers were given support on breastfeeding, breast problems were addressed, and information was given to support the mother's self-efficacy.
Study NCT06341140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet containing information about breastfeeding
Description: Pregnant women in the control group were given only a breastfeeding booklet, breastfeeding status, breast problems and breastfeeding self-efficacy were evaluated during postnatal home visits and telephone interviews, and risky situations were referred to health professionals.
Study NCT04895852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: The self-adhesive gel electrode pad will be placed at the center of DU20 (Baihui), EX-HN3 (Yintang) and both sides of LI4 (Hegu), LR3 (Taichong) in strict accordance with the World Health Organization Standardized Acupuncture Location. Electric stimulation will be used with a TEAS apparatus (HANS200A Beijing Huawei Co., LTD.) . The frequency of the electrical stimulation will be set as alternating 2/100Hz to relieve anxiety. The current intensity will be adjusted individually, starting at 1 mA and increasing gradually until the patient can perceive and tolerate it (preferably slight twitching of local muscles without pain).
Study NCT05534724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Partial weight-bearing (10 - 15kg)
Description: Immediate post-operative partial weight-bearing (10 - 15kg) with a VACOPASO shoe for 6 weeks
Study NCT05534724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complete weight-bearing
Description: Complete post-operative weight-bearing with a VACOPASO shoe for 6 weeks
Study NCT04895852 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TEAS
Description: The STEAS group selects the same acupoints as the TEAS group and other intervention measures are the same as the TEAS group except for the current intensity is set to 0-mA. The acupuncturist responsible for the operation will tell patients in STEAS group that this is a type of stimulus without perception.
Study NCT06783127 — intervention group
Intervention type: DRUG
Intervention: Olaparib
Description: Olaparib given according the clinical practice to BRCA positive mCRPC patients
Study NCT06499324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA group
Description: It consists of a blind injection of 288 IU (/144mL) of BTA (XEOMIN®) into the lateral muscles (18 injection sites, 16UI/8mL/injection site), 4 to 6 weeks before the treatment of a large anterior IH (width ≥ 10 cm) with open non absorbable mesh repair. The injection of BTA (XEOMIN®) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the BTA group, 3 vials of 100 equivalent IU of BTA (XEOMIN® 100U), diluted to 2 IU/mL with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of BTA solution (144 IU) will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
Study NCT06499324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: It consists of a blind injection of placebo of BTA (XEOMIN® 100U matching placebo) into the lateral muscles (18 injection sites, 8mL/injection site), 4 to 6 weeks before the treatment of a large IH (width >= 10 cm) with open non absorbable mesh repair. The injection of placebo of BTA (XEOMIN® 100U matching placebo) will be done during an outpatient hospitalization, in each of the 3 lateral muscles of the abdomen on each side. To do this in the control group, 3 vials of placebo of BTA (XEOMIN® 100U matching placebo), diluted with 0.9% saline will be distributed in 3 syringes of 50 mL equipped with a 21G needle. A total of 72 mL of placebo of BTA solution will be injected on each side, at 3 injection points between the costal rim and iliac crest, under ultrasound control.
Study NCT06292208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBD0333
Description: This is a phase I/II, open, non-randomized, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and preliminary efficacy of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma in dose-escalation, dose-expansion, and clinical exploration phases.
Study NCT05999890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tapentadol Hydrochloride
Description: Intranasal administration of tapentadol was compared with intravenous paracetamol for postoperative analgesia
Study NCT05999890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol Hydrochloride
Description: Intranasal administration of tapentadol was compared with intravenous paracetamol for postoperative analgesia
Study NCT04962087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Health enSuite Insomnia
Description: Health enSuite: Insomnia has been designed based on established cognitive behavioural treatments for insomnia and adapted to fit an automated interactive platform available via an internet enabled device. The program is divided into a series of treatment modules or levels that will be delivered over the course of 6-8 weeks. The content of these 6 levels includes the following components, a sleep diary, sleep restriction clock, sleep hygiene, relaxation techniques, sleep related thoughts and beliefs, and involving a support person.
Study NCT04962087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Health enSuite Insomnia - Deprescribing
Description: All participants in Trial 2 will be initiating a gradual medication tapering schedule recommended to them by their physician. The module physicians use to refer their patients to the study includes a section where they fill out a brief drug history for sleep medications. This information is then used to generate a tapering schedule that the health care provider will review with their patient. Health care providers are responsible for providing appropriate medication counselling and follow-up care to supervise deprescribing. This study does not place any restriction on the usual care participants will receive.
Study NCT06044246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF membrane
Description: Placing implant with PRF membrane treatment
Study NCT06050642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced care model provided by Timkl, a home support provider
Description: A new type of care provided by timkl, a home support provider, involving nurses and the dispensing pharmacist. This approach combines the current tasks of the service provider's nurses with closer monitoring by the pharmacist, thanks to more frequent contacts and a holistic view of the patient.
Study NCT05989919 — intervention group
Intervention type: OTHER
Intervention: CT scan for nose and paranasal sinuses
Description: CT scan for nose and paranasal sinuses
Study NCT05977868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid
Description: COpAT (oral antimicrobial therapy) on hospital discharge
Study NCT05977868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Description: Standard of care (IV antimicrobial therapy) on hospital discharge
Study NCT04844983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
Study NCT04020055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl 150 mg
Description: migalastat HCl 150 mg capsule
Study NCT04844983 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Saline
Description: Normal Saline
Study NCT05242536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse- led program
Description: A nurse coordinated multidisciplinary program aiming to improve psychosocial problems has been developed and will be applied to the patients in the experimental group. This nurse-led program will start at discharge and continue for three months.
Study NCT05337995 — intervention group
Intervention type: OTHER
Intervention: Quantified analysis of walking during a task of passage through a horizontal opening
Description: Functional test that reproduce a task of daily living, similar to a doorway
Study NCT06218342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin
Description: Besides lifestyle intervention and background medication, participants will be prescribed Henagliflozin at standard clinical doses.
Study NCT06218342 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Background medication
Description: Participants will only receive lifestyle intervention and background medication.
Study NCT05384249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study NCT05384249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study NCT06417762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Science Communication Curriculum Cohort 1
Description: Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy
Study NCT06417762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Science communication curriculum Cohort 2
Description: Promotores will receive a tailored curriculum on how to debunk misinformation and create infographics and media as well as incorporate their personal narratives into social media posts for their communities. Each session will be taught by a bilingual instructor and will be recorded for later consultation and viewing. Sessions will be 2 hours in length and will require an additional 1h of pre-work for each session. Together, each cohort will participate in 18 hours of training as follows: Session 1: What is Misinformation? How do participants identify myths? Session 2: The Power of Storytelling, Present their myth. Session 3: Workshop: Review myths and storyboard for each person with feedback. Session 4: Infographics: Teaching creation of infographics on Canva (free to use).~Session 5: Workshop: Present draft infographic and discuss preliminary social media strategy Session 6: Final Product: Share final infographic and final post / social media strategy